Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Non-Current Deffered Revenue (2021 - 2025)

Zymeworks' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $14.6 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.01% to $14.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.6 million, a 0.01% change, with the full-year FY2025 number at $14.6 million, changed 0.01% from a year prior.
  • Non-Current Deffered Revenue hit $14.6 million in Q4 2025 for Zymeworks, roughly flat from $14.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ZYME hit a ceiling of $32.9 million in Q4 2021 and a floor of $14.6 million in Q4 2025.
  • Historically, Non-Current Deffered Revenue has averaged $25.1 million across 5 years, with a median of $30.6 million in 2022.
  • Biggest five-year swings in Non-Current Deffered Revenue: rose 7.69% in 2023 and later tumbled 55.66% in 2024.
  • Tracing ZYME's Non-Current Deffered Revenue over 5 years: stood at $32.9 million in 2021, then dropped by 7.14% to $30.6 million in 2022, then increased by 7.69% to $32.9 million in 2023, then tumbled by 55.66% to $14.6 million in 2024, then dropped by 0.01% to $14.6 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ZYME at $14.6 million in Q4 2025, $14.6 million in Q3 2025, and $14.6 million in Q2 2025.